These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27010343)

  • 1. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
    Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
    Barco S; Schmidtmann I; Ageno W; Bauersachs RM; Becattini C; Bernardi E; Beyer-Westendorf J; Bonacchini L; Brachmann J; Christ M; Czihal M; Duerschmied D; Empen K; Espinola-Klein C; Ficker JH; Fonseca C; Genth-Zotz S; Jiménez D; Harjola VP; Held M; Iogna Prat L; Lange TJ; Manolis A; Meyer A; Mustonen P; Rauch-Kroehnert U; Ruiz-Artacho P; Schellong S; Schwaiblmair M; Stahrenberg R; Westerweel PE; Wild PS; Konstantinides SV; Lankeit M;
    Eur Heart J; 2020 Jan; 41(4):509-518. PubMed ID: 31120118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
    Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
    Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency Department Discharge of Pulmonary Embolus Patients.
    Frank Peacock W; Coleman CI; Diercks DB; Francis S; Kabrhel C; Keay C; Kline JA; Manteuffel J; Wildgoose P; Xiang J; Singer AJ
    Acad Emerg Med; 2018 Sep; 25(9):995-1003. PubMed ID: 29757489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban plus Percutaneous catheter-directed treatment for a patient with massive pulmonary embolism and colporrhagia.
    Wang W
    Am J Emerg Med; 2018 Aug; 36(8):1522.e5-1522.e7. PubMed ID: 29709396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis.
    Beam DM; Kahler ZP; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):788-95. PubMed ID: 26113241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible Rivaroxaban Failure during the Postpartum Period.
    Rudd KM; Winans AR; Panneerselvam N
    Pharmacotherapy; 2015 Nov; 35(11):e164-8. PubMed ID: 26598101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism: A retrospective study.
    Wang L; Jiang S; Li C; Xu Z; Chen Y
    Medicine (Baltimore); 2021 Apr; 100(13):e25086. PubMed ID: 33787591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
    Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
    Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.